Cubist Pharmaceuticals, Inc. (CBST) news stock charts
Cubist Pharmaceuticals, Inc. (CBST) Investment Summary:
Cubist Pharmaceuticals, Inc., which we refer to as "Cubist" or the "Company", was incorporated in Delaware in 1992. We completed our initial public offering in 1996, and our shares are listed on the NASDAQ Global Select Market, where our symbol is CBST. Our principal offices are located at 65 Hayden Avenue, Lexington, Massachusetts. Our telephone number is 781-860-8660, and our website address is www.cubist.com. Corporate Overview and Business Strategy Cubist is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. To date, we have concentrated exclusively on developing products for the anti-infective marketplace. Cubist has one marketed product, an intravenous (IV) antibiotic, CUBICIN® (daptomycin for injection), which was launched in the U.S. in November 2003. CUBICIN is approved in the U.S. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f29%2f0001047469-08-002102.html#FIS_BUSINESS"www.cubist.com
600 Employees
Founded in 1992
CUBIST PHARMACEUTICALS INC (CBST:NASDAQ)
LAST $22.69 USD
CHANGE TODAY -0.25 -1.09%
VOLUME 892.7K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CUBIST PHARMACEUTICALS INC (CBST)
|
OPEN
$23.00
|
PREVIOUS CLOSE
$22.94
|
|
|
DAY HIGH
$23.22
|
DAY LOW
$22.69
|
|
|
52 WEEK HIGH
03/19/10 - $23.22
|
52 WEEK LOW
03/25/09 - $15.59
|
|
|
MARKET CAP
1.3B
|
AVERAGE VOLUME 10 D
450.7K
|
|
|
EPS TTM
$2.12
|
SHARES OUTSTANDING
58.0M
|
|
|
CBST Does Not Pay Dividends
|
P/E TTM
10.7x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks on the Move: BofA, Citigroup, Comcast
12/03/2009 10:22 AM ET
Plus more stocks making headlines in Thursday's market
Key developments for CUBIST PHARMACEUTICALS INC (CBST)
Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals
02/25/2010
Evotec AG announced that it has extended its research agreement with Cubist Pharmaceuticals Inc. to the end of 2010. Under the contract extension, Evotec will provide additional fragment-based drug discovery expertise using its proprietary platform, EVOlution, which includes fragment screening, structural biology and protein crystallography, to discover and profile novel compounds against additional antibacterial targets selected by Cubist. Evotec and Cubist have collaborated since July 2009, successfully progressing drug discovery programmes. Over the course of 2010, Evotec will continue and expand its support of Cubist's discovery activities. A key benefit of Evotec's fragment-based drug discovery platform is its versatility, combining biochemical and biophysical techniques including nuclear magnetic resonance, surface plasmon resonance and x-ray crystallography, thus allowing the design of target-specific strategies. No financial details are disclosed.
Cubist Pharmaceuticals Appoints Lonnie Moulder to its Board of Directors
02/22/2010
Cubist Pharmaceuticals Inc. announced the appointment of Leon (Lonnie) Moulder Jr. to its board of directors. Most recently, Mr. Moulder served as Vice Chairman, President and Chief Executive Officer of Abraxis BioScience Inc. from April 2009 to January 2010. Previously, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America from January 2008 until January 2009, after Eisai acquired MGI PHARMA Inc. where he had served consecutively as Executive Vice President, President and Chief Operating Officer, and President and Chief Executive Officer from September 1999 to January 2008.
Cubist Pharmaceuticals Inc. Presents at BioNetwork East 2010, Mar-15-2010 through Mar-17-2010
02/12/2010
Cubist Pharmaceuticals Inc. Presents at BioNetwork East 2010, Mar-15-2010 through Mar-17-2010. Venue: Eden Roc Resort and Spa, 4525 Collins Avenue, Miami Beach, FL 33140, United States.
Cubist Pharmaceuticals, Inc. financial resources
CBST Competitors
| Company | Last | Change |
| Celera Corp | $6.92 USD | +0.04 |
| Ceragenix Pharmaceuticals Inc | $0.40 USD | 0.00 |
| Inhibitex Inc | $1.30 USD | -0.06 |
| Oragenics Inc | $0.67 USD | +0.05 |
| PolyMedix Inc | $1.22 USD | +0.04 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CBST | Industry Range |
| Price/Earnings | 19.5x |
|
| Price/Sales | 2.3x |
|
| Price/Book | 2.8x |
|
| Price/Cash Flow | 16.6x |
|
| TEV/Sales | 1.3x |
|
|
CBST |
||
|
CBST transactions
| Type Date |
Target |
|
Merger/Acquisition
December 12, 2009 |
Calixa Therapeutics, Inc. |
|
Private Placement
November 16, 2009 |
FORMA Therapeutics, Inc. |
More Recent Financial News About Cubist Pharmaceuticals, Inc.
Cubist Pharmaceuticals President and CEO Michael Bonney Honored by Massachusetts Biotechnology Council with its 2010 Innovative Leadership Award
2010-03-17 05:42:55
Quote: Press ReleaseSource: Cubist Pharmaceuticals, Inc.On Monday March 15, 2010, 1:30 pm EDTLEXINGTON, Mass.--(BUSINESS WIRE)-- (:- ) today announced that itsPresident and CEO Michael Bonney will be honored with the second annualMassachusetts Biotechnology Council (MassBio) Innovative LeadershipAward. Mr. Bonney will receive this recognition at an awards luncheon atthe MassBio Annual Meeting on March 31Last year, Cubist garnered several plaudits, including the top spot inthe MassEcon Sixth Annual Team...Read article
Cubist Pharmaceuticals President and CEO Michael Bonney Honored by Massachusetts Biotechnology Council with its 2010 Innovative Leadership Award
2010-03-16 04:02:17
Quote: Press ReleaseSource: Cubist Pharmaceuticals, Inc.On Monday March 15, 2010, 1:30 pm EDTLEXINGTON, Mass.--(BUSINESS WIRE)-- (:- ) today announced that itsPresident and CEO Michael Bonney will be honored with the second annualMassachusetts Biotechnology Council (MassBio) Innovative LeadershipAward. Mr. Bonney will receive this recognition at an awards luncheon atthe MassBio Annual Meeting on March 31Last year, Cubist garnered several plaudits, including the top spot inthe MassEcon Sixth Annual Team...Read article
Cubist Pharmaceuticals Appoints Lonnie Moulder to its Board of Directors
2010-03-08 03:57:08
Quote: Press ReleaseSource: Cubist PharmaceuticalsOn Monday February 22, 2010, 9:01 am ESTLEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (:- Previously, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America from January 2008 until January 2009, after Eisai acquired MGI PHARMA, Inc., where he had served consecutively as Executive Vice President, President and Chief Operating Officer, and President and Chief Executive Officer from1999 to January 2008. Prior to joining...Read article
Cubist Pharmaceuticals to Present at March 2010 Investor Conferences
2010-03-08 03:57:08
Quote: Press ReleaseSource: Cubist Pharmaceuticals, Inc.On Wednesday February 17, 2010, 12:04 pm ESTLEXINGTON, Mass.--(BUSINESS WIRE)--. (:- ) today announced that David McGirr, Cubist’s SVP and CFO, will participate on a panel — Building on Success — Tuesday, March 2Cubist also announced that Michael Bonney, President and CEO of Cubist, will present on Monday March 8, 2010, at 3:15 p.m. ET, at the Cowen and Company 30Both of the presentations are accessible through Cubist's websit...Read article
Evotec Extends and Broadens Research Agreement With Cubist Pharmaceuticals
2010-03-08 03:57:07
Quote: Read article
Cubist 4Q profit tumbles without tax benefit
2010-02-26 03:12:08
Quote: (AP) -- Cubist Pharmaceuticals Inc. reported Thursday that its fourth-quarter profit dropped 76 percent from a year-ago period helped by a hefty tax benefit, but said sales of its antibiotic Cubicin sharply increased.The company said its profit shrank to $22.7 million, or 38 cents per share, from $94.5 million, or $1.43 per share, in the year-ago quarter, which included a $127.8 million tax gain.Revenue rose 27 percent to $166.7 million from $131.2 million, with U.S. sales of Cubicin growing 23 ...Read article
Evotec Extends and Broadens Research Agreement With Cubist Pharmaceuticals
2010-02-26 03:12:04
Quote: Read article
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
2010-02-26 03:12:04
Quote: Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of New Director
On February 18, 2010, Cubist Pharmaceuticals, Inc. ("Cubist") appointed Lonnie
(Leon) Moulder Jr. to its Board of Directors (the "Board").From April 2009 to
January 2010, Mr. Moulder was Vice Chairman, President and Chief Executive
Officer of Abraxis BioScience, Inc.Before that, Mr. Mould...Read article
Cubist Pharmaceuticals Appoints Lonnie Moulder to its Board of Directors
2010-02-23 02:18:28
Quote: Press ReleaseSource: Cubist PharmaceuticalsOn Monday February 22, 2010, 9:01 am ESTLEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ:- Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe research, development, and commercialization of pharmaceuticalproducts that address unmet medical needs in the acute care environment.In the U.S., Cubist markets CUBICIN® (daptomycin for injection), thefirst antibiotic in a new class of anti-infectives called lipope...Read article
Cubist Pharmaceuticals to Present at March 2010 Investor Conferences
2010-02-18 03:20:16
Quote: Press ReleaseSource: Cubist Pharmaceuticals, Inc.On Wednesday February 17, 2010, 12:04 pm ESTLEXINGTON, Mass.--(BUSINESS WIRE)--. (NASDAQ:- ) today announced that DavidMcGirr, Cubist’s SVP and CFO, will participate on a panel — Building onSuccess — Tuesday, March 2Cubist also announced that Michael Bonney, President and CEO of Cubist,will present on Monday March 8, 2010, at 3:15 p.m. ET, atthe Cowen and Company 30Both of the presentations are accessible through Cubist's webs...Read article
Q4 2009 Cubist Pharmaceuticals, Inc. Earnings Release - Time Not Supplied
2010-01-22 01:01:26
Quote: Read article
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
2010-01-22 01:01:25
Quote: Read article
Cubist 4Q profit tumbles without tax benefit
2010-01-22 01:01:24
Quote: (AP) -- Cubist Pharmaceuticals Inc. reported Thursday that its fourth-quarter profit dropped 76 percent from a year-ago period helped by a hefty tax benefit, but said sales of its antibiotic Cubicin sharply increased.The company said its profit shrank to $22.7 million, or 38 cents per share, from $94.5 million, or $1.43 per share, in the year-ago quarter, which included a $127.8 million tax gain.Revenue rose 27 percent to $166.7 million from $131.2 million, with U.S. sales of Cubicin growing 23 ...Read article
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
2010-01-22 01:01:24
Quote: CUBIST PHARMACEUTICALS INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
CUBIST PHARMACEUTICALS INC
21-Jan-2010Results of Operations and Financial Condition, Financial Statements an
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent provide...Read article
InPlay: Cubist Pharma misses by $0.03, reports revs in-line
2010-01-22 01:01:24
Keywords: market update, investing education, financial advice, financial planning
Quote: Read article
Cubist Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
2010-01-22 01:01:23
Quote: Cubist Pharmaceuticals, Inc. (CBST)
Q4 2009 Earnings Call Transcript
January 21, 2009 5:00 pm ET
Executives
Eileen McIntyre – Senior Director, Corporate Communications
David McGirr – SVP & CFO
Rob Perez – EVP & COO
Steve Gilman – SVP, Discovery & Nonclinical Development and Chief Scientific Officer
Mike Bonney – President & CEO
Analysts
Eun Yang – Jefferies & Company
Joel Sendek – Lazard Capital Markets
Alan Carr – Needh...Read article
Cubist drug Cubicin posted $524M in '09 sales
2010-01-14 03:59:15
Quote: Cubist Pharmaceuticals Inc. said its Cubicin therapy for skin infections generated $524 million in net revenue last year, a 26 percent spike over fiscal 2008’s take.The Lexington, Mass.-based company said Cubicin’s sales in the fourth quarter were $147 million, up 23 percent, or $27.7 million, on a year-over-year basis. The full-year’s revenue performance was some $109.3 million above 2008’s total revenue of around $415 million.Cubist said international product sales tota...Read article
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
2010-01-14 03:59:15
Quote: Item 2.02 Results of Operations and Financial Condition.
On January 11, 2010, the registrant, Cubist Pharmaceuticals, Inc. ("Cubist"),
issued a press release reporting its total unaudited net revenues for the year
ended December 31, 2009.The press release also reported Cubist's total
unaudited net revenues from sales of CUBICIN® (daptomycin for injection) in the
United States for the quarter and year ended December 31, 2009, Cubist's share
of international net product revenues (unaud...Read article
Cubist Pharmaceuticals and the New England Patriots Radio Network Recognize Innovative Science Teachers
2010-01-13 04:13:40
Quote: Press ReleaseSource: Cubist Pharmaceuticals, Inc.On Monday December 28, 2009, 12:06 pm ESTLEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ:- ) today announced that itspartnership with the New England Patriots Radio Network, WBZ FM 98.5 , to recognize innovative science teachers in middleschools and high schools throughout New England selected 11 science“Teachers of the Week†during the course of the football season. Theseason’s winning teacher, who was r...Read article
Would you like to leave a comment about Cubist Pharmaceuticals, Inc. CBST
Find out what social network information about Cubist Pharmaceuticals, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Cubist Pharmaceuticals, Inc.'s Stock there is more great penny stock and market information at Realpennies